Literature DB >> 26774390

Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET.

Maruta Bunka1, Cristina Müller2, Christiaan Vermeulen3, Stephanie Haller3, Andreas Türler1, Roger Schibli4, Nicholas P van der Meulen5.   

Abstract

PET is the favored nuclear imaging technique because of the high sensitivity and resolution it provides, as well as the possibility for quantification of accumulated radioactivity. (44)Sc (T1/2=3.97h, Eβ(+)=632keV) was recently proposed as a potentially interesting radionuclide for PET. The aim of this study was to investigate the image quality, which can be obtained with (44)Sc, and compare it with five other, frequently employed PET nuclides using Derenzo phantoms and a small-animal PET scanner. The radionuclides were produced at the medical cyclotron at CRS, ETH Zurich ((11)C, (18)F), at the Injector II research cyclotron at CRS, PSI ((64)Cu, (89)Zr, (44)Sc), as well as via a generator system ((68)Ga). Derenzo phantoms, containing solutions of each of these radionuclides, were scanned using a GE Healthcare eXplore VISTA small-animal PET scanner. The image resolution was determined for each nuclide by analysis of the intensity signal using the reconstructed PET data of a hole diameter of 1.3mm. The image quality of (44)Sc was compared to five frequently-used PET radionuclides. In agreement with the positron range, an increasing relative resolution was determined in the sequence of (68)Ga<(44)Sc<(89)Zr<(11)C<(64)Cu<(18)F. The performance of (44)Sc was in agreement with the theoretical expectations based on the energy of the emitted positrons.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (11)C; (18)F; (44)Sc; (64)Cu; (68)Ga; (89)Zr; PET; Phantom; Resolution

Mesh:

Substances:

Year:  2016        PMID: 26774390     DOI: 10.1016/j.apradiso.2016.01.006

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  9 in total

1.  NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system.

Authors:  Shuguang Chen; Yushen Gu; Haojun Yu; Xin Chen; Tuoyu Cao; Lingzhi Hu; Hongcheng Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-03       Impact factor: 9.236

2.  The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides.

Authors:  L M Carter; Adam Leon Kesner; E C Pratt; V A Sanders; A V F Massicano; C S Cutler; S E Lapi; Jason S Lewis
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

Review 3.  Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection.

Authors:  Lukas M Carter; Sophie Poty; Sai Kiran Sharma; Jason S Lewis
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-30       Impact factor: 1.921

4.  Synthesis, radiolabeling, and pre-clinical evaluation of [44Sc]Sc-AAZTA conjugate PSMA inhibitor, a new tracer for high-efficiency imaging of prostate cancer.

Authors:  S Ghiani; I Hawala; D Szikra; G Trencsényi; Z Baranyai; G Nagy; A Vágner; R Stefania; S Pandey; A Maiocchi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-09       Impact factor: 9.236

5.  44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617.

Authors:  Christoph A Umbricht; Martina Benešová; Raffaella M Schmid; Andreas Türler; Roger Schibli; Nicholas P van der Meulen; Cristina Müller
Journal:  EJNMMI Res       Date:  2017-01-19       Impact factor: 3.138

6.  Production and separation of 43Sc for radiopharmaceutical purposes.

Authors:  Katharina A Domnanich; Robert Eichler; Cristina Müller; Sara Jordi; Vera Yakusheva; Saverio Braccini; Martin Behe; Roger Schibli; Andreas Türler; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2017-11-25

Review 7.  Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.

Authors:  R Mikolajczak; S Huclier-Markai; C Alliot; F Haddad; D Szikra; V Forgacs; P Garnuszek
Journal:  EJNMMI Radiopharm Chem       Date:  2021-05-25

8.  PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [68Ga]Ga-NODAGA-AMBA and [44Sc]Sc-NODAGA-AMBA.

Authors:  Ibolya Kálmán-Szabó; Judit P Szabó; Viktória Arató; Noémi Dénes; Gábor Opposits; István Jószai; István Kertész; Zita Képes; Anikó Fekete; Dezső Szikra; István Hajdu; György Trencsényi
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

Review 9.  Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review.

Authors:  Salam Awenat; Arnoldo Piccardo; Patricia Carvoeiras; Giovanni Signore; Luca Giovanella; John O Prior; Giorgio Treglia
Journal:  Diagnostics (Basel)       Date:  2021-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.